OCUGEN, INC. Long-Term Debt, Maturity, Year Two
OCUGEN, INC. (OCGN) had Long-Term Debt, Maturity, Year Two of $13.75 million as of 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2026-05-08
- 2026-03-31: Long-Term Debt, Maturity, Year Two $13.75M.
- 2025-12-31: Long-Term Debt, Maturity, Year Two $16.00M.
- 2025-09-30: Long-Term Debt, Maturity, Year Two $16.00M.
- 2025-06-30: Long-Term Debt, Maturity, Year Two $16.00M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2026-03-31 | $13.75M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $16.00M 10-K · filed 2026-03-04 |
| 2025-09-30 | $16.00M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $16.00M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $16.00M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $1.25M 10-K · filed 2025-03-05 |
| 2020-12-31 | $187.30K 10-K · filed 2021-03-19 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-06 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-14 |
| 2017-09-30 | $178.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $178.00K 10-Q · filed 2017-08-10 |
| 2017-03-31 | $178.00K 10-Q · filed 2017-05-11 |
| 2016-09-30 | $583.00K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $583.00K 10-Q · filed 2016-08-11 |
| 2016-03-31 | $583.00K 10-Q · filed 2016-05-12 |
| 2015-12-31 | $583.00K 10-Q · filed 2016-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |